Skip to main content

Volume 14 Supplement 5

B cells in autoimmune diseases: Part 1


The supplement was proposed by the journal and content was developed in consultation with the Editor-in-Chief. Articles have been independently prepared by the authors and have undergone the journal's standard peer review process. Publication of the supplement was supported by Medimmune.

This supplement has been published in two parts. Part 2 is available at

  1. Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and h...

    Authors: Henrik E Mei, Stefanie Schmidt and Thomas Dörner
    Citation: Arthritis Research & Therapy 2012 14(Suppl 5):S1

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2022 Speed
    9 days submission to first editorial decision for all manuscripts (Median)
    149 days submission to accept (Median)

    2022 Usage 
    17,226 Altmetric mentions